[1]王颖 唐晓男 王会宜 崔艳慧 曹飞 康小红.华蟾素胶囊联合吉非替尼对晚期肺癌患者临床疗效及血清miR-221表达的影响[J].陕西中医药大学学报,2021,44(06):084-88.[doi:10.13424/j.cnki.jsctcm.2021.06.017]
　WANG Ying TANG Xiaonan WANG Huiyi CUI Yanhui CAO Fei KANG Xiaohong.Effect of Cinobufagin Capsule Combined withGefitinib on Clinical Efficacy and Serum miR221Expression in Patients with Advanced Lung Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,44(06):084-88.[doi:10.13424/j.cnki.jsctcm.2021.06.017]
点击复制

华蟾素胶囊联合吉非替尼对晚期肺癌患者临床疗效及血清miR-221表达的影响
分享到：

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
44
期数:
2021年06期
页码:
084-88
栏目:
论著
出版日期:
2021-11-30

文章信息/Info

Title:
Effect of Cinobufagin Capsule Combined with Gefitinib on Clinical Efficacy and Serum miR221 Expression in Patients with Advanced Lung Cancer
文章编号:
2096-1340(2021)06-0084-05
作者:
王颖1 唐晓男1 王会宜1 崔艳慧1 曹飞2 康小红1
1.新乡医学院第一附属医院肿瘤科，河南 新乡 453100；
2.平顶山市第一人民医院肿瘤研究中心，河南 平顶山 467000
Author(s):
WANG Ying1 TANG Xiaonan1 WANG Huiyi1 CUI Yanhui1 CAO Fei2 KANG Xiaohong1
1. Department of Oncology，The First Affiliated Hospital of Xinxiang Medical College，Henan Xinxiang 453100,China;
2. Cancer Research Center of Pingdingshan First Peoples Hospital，Henan Pingdingshan 467000，China
关键词:
关键词：肺癌; 华蟾素胶囊; 吉非替尼; 微小RNA221; 耐药
Keywords:
Key words： Lung cancer;  Cinobufagin capsule;  Gefitinib;  miR-221;  Drug resistance
分类号:
R734.2
DOI:
10.13424/j.cnki.jsctcm.2021.06.017
文献标志码:
A
摘要:
摘 要：目的 探讨华蟾素胶囊联合吉非替尼对晚期表皮生长因子受体（EGFR）突变的非小细胞肺癌患者临床疗效及血清miR221的影响。方法 选取2016年6月—2018年6月就诊于新乡医学院第一附属医院肿瘤科的晚期EGFR突变的NSCLC患者75例，随机分为吉非替尼治疗组（对照组，37例）和华蟾素胶囊+吉非替尼治疗组（治疗组，38例），观察两组患者临床疗效、不良反应、无疾病生存期（PFS）及血清miR221表达情况。结果 对照组部分缓解（PR）为62.1%，疾病稳定（SD）为21.6%，疾病进展（PD）为8.1%，客观有效率（ORR）为621%，疾病控制率（DCR）为83.7%；治疗组PR为65.8%，SD为26.3%，PD为5.2%，ORR为65.8%，DCR为921%，两组相比，ORR无明显差异，但DCR差异显著（P＜0.01）；对照组中位PFS为10.1个月，治疗组中位PFS为12.6个月，两组相比，差异显著（P＜0.01）；两组患者皮疹、腹泻、肝功能损伤等不良反应发生率方面比较，无明显差异（P＞0.05）；对照组疾病进展后miR221相对表达水平为8.05±0.06，与治疗前3.01±0.02相比，显著升高（P＜0.01）；治疗组患者疾病进展后miR221相对表达水平为6.32±0.03，与对照组相比8.05±006，显著降低（P＜0.05）。结论 华蟾素胶囊联合吉非替尼可提高EGFR突变的晚期非小细胞肺癌临床疗效，延长PFS，下调血清miR221表达水平，具有延缓吉非替尼耐药的作用。
Abstract:
Abstract： Objective To investigate the effect of cinobufagin capsule combined with gefitinib on the clinical efficacy and serum miR-221 of patients with advanced epidermal growth factor receptor (EGFR) mutation in nonsmall cell lung cancer. Methods 75 NSCLC patients with advanced EGFR mutation treated in the oncology department of the First Affiliated Hospital of Xinxiang Medical College from June 2016 to June 2018 were randomly divided into gefitinib treatment group (control group，37 cases) and Cinobufacin capsule + gefitinib treatment group (treatment group，38 cases). The clinical efficacy，adverse reactions and diseasefree survival (PFS)，the expression of serum miR-221of the two groups were observed. Results In the control group，the partial remission (PR) was 62.1%，the disease stability (SD) was 216%，the disease progression (PD) was 8.1%，the objective effective rate (ORR) was 62.1%，and the disease control rate (DCR) was 83.7%; In the treatment group，PR was 65.8%，SD was 26.3%，PD was 5.2%，ORR was 65.8% and DCR was 92.1%. There was no significant difference in ORR between the two groups，but there was significant difference in DCR (P<0.01); The median PFS in the control group was 10.1 months and that in the treatment group was 12.6 months. There was significant difference between the two groups (P<0.01); There was no significant difference in the incidence of skin rash，diarrhea and liver function injury between the two groups (P＞0.05); The relative expression level of miR-221 in the control group was 8.05±0.06，which was significantly higher than that before treatment (3.01±0-02) (P<0.01); The relative expression level of miR-221 in the treatment group was 6.32±0.03，which was significantly lower than that in the control group (8.05±0.06) (P<0.05). Conclusion Cinobufagin capsule combined with gefitinib can improve the clinical efficacy of EGFR mutant advanced nonsmall cell lung cancer，prolong PFS，down regulate the expression level of serum miR-221，and delay the drug resistance of gefitinib. Abstract： Objective To investigate the effect of cinobufagin capsule combined with gefitinib on the clinical efficacy and serum miR-221 of patients with advanced epidermal growth factor receptor (EGFR) mutation in nonsmall cell lung cancer. Methods 75 NSCLC patients with advanced EGFR mutation treated in the oncology department of the First Affiliated Hospital of Xinxiang Medical College from June 2016 to June 2018 were randomly divided into gefitinib treatment group (control group，37 cases) and Cinobufacin capsule + gefitinib treatment group (treatment group，38 cases). The clinical efficacy，adverse reactions and diseasefree survival (PFS)，the expression of serum miR-221of the two groups were observed. Results In the control group，the partial remission (PR) was 62.1%，the disease stability (SD) was 216%，the disease progression (PD) was 8.1%，the objective effective rate (ORR) was 62.1%，and the disease control rate (DCR) was 83.7%; In the treatment group，PR was 65.8%，SD was 26.3%，PD was 5.2%，ORR was 65.8% and DCR was 92.1%. There was no significant difference in ORR between the two groups，but there was significant difference in DCR (P<0.01); The median PFS in the control group was 10.1 months and that in the treatment group was 12.6 months. There was significant difference between the two groups (P<0.01); There was no significant difference in the incidence of skin rash，diarrhea and liver function injury between the two groups (P＞0.05); The relative expression level of miR221 in the control group was 8.05±0.06，which was significantly higher than that before treatment (3.01±0-02) (P<0.01); The relative expression level of miR-221 in the treatment group was 6.32±0.03，which was significantly lower than that in the control group (8.05±0.06) (P<0.05). Conclusion Cinobufagin capsule combined with gefitinib can improve the clinical efficacy of EGFR mutant advanced nonsmall cell lung cancer，prolong PFS，down regulate the expression level of serum miR-221，and delay the drug resistance of gefitinib.

参考文献/References:

［1］Siegel RL，Miller KD，Jemal A.Cancer statistics，2020［J］.CA Cancer J Clin，2020，70(1):7-30.
［2］Ohashi K，Maruvka YE，Michor F，et al.Epidermal growth factor receptor tyrosine kinase inhibitorresistant disease［J］.J Clin Oncol，2013，31(8):1070-1080.
［3］Maione P，Sacco PC，Sgambato A，et al.Overcoming resistance to targeted therapies in NSCLC:current approaches and clinical application［J］.Ther AdvMed Oncol，2015,7(5):263-273.
［4］Popat S.Osimertinib as FirstLine Treatment in EGFRMutated NonSmallCell Lung Cancer［J］.N Engl J Med，2018,378(2):192-193.
［5］原发性肺癌诊疗规范(2018年版)［J］.肿瘤综合治疗电子杂志,2019,5(3):100-120.
［6］Goldstraw P，Chansky K，Crowley J，et al.The IASLC Lung Cancer Staging Project:Proposals for Revision of the TNM Stage Groupings in the Forthcoming(Eighth) Edition of the TNM Classification for Lung Cancer［J］.J Thorac Oncol,2016,11(1):39-51.
［7］Eisenhauer EA,Therasse P，Bogaerts J，et al.New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1)［J］，Eur J Cancer,2009,45(2):228-247.
［8］Shimizu T，Saijo N.Common toxicity criteria：version 2.0，an improved reference for grading the adverse reaction of cancer treatment［J］.Nihon Rinsho，2003,61(6):937-942.
［9］樊李瀛，衡立松，段虹昊，等.骨肉瘤患者肿瘤组织中PLOD2基因表达水平及其对肿瘤细胞迁移/侵袭的影响［J］.临床和实验医学杂志，2019，18(24):2589-2593.
［10］朱必胜,田红岸,舒诚荣,等.华蟾素胶囊联合放疗治疗晚期胰腺癌的临床效果观察［J］.中国医药，2020，15(5):749-752.
［11］李现忠.华蟾素胶囊联合化疗对晚期非小细胞肺癌患者的疗效［J］.实用中西医结合临床，2020,20(3):47-48.
［12］陈进宝,殷佩浩.蟾毒灵抗肿瘤作用分子机制的研究进展［J］.河北中医,2019,41(1):140-145.
［13］Kang XH，Xu ZY，Gong YB，et al.Bufalin Reverses HGF-Induced Resistance to EGFRTKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis［J］.EvidenceBased Complementary and Alternative Medicine，2013:243859.
［14］康小红,路平,崔艳慧,等.蟾毒灵对肝细胞生长因子诱导的阿法替尼耐药的逆转作用［J］.中华肿瘤杂志,2015,37(7):490-496.
［15］Liu M，Liu J，Wang L，et al.Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival［J］.PLoS One,2014,（9）:e109347.
［16］Zheng Q，Peskoe SB，Ribas J，et al.Investigation of miR21，miR141,and miR221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy［J］.Prostate,2014,（74）:1655-1662.
［17］高园园，康小红，王颖，等.微RNA221诱导PC9肺癌细胞对吉非替尼的耐药机制［J］.中华医学杂志，2018,98(42):3447-3452.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金项目（82074268，81503414，81874392，82074231）；河南省医学科技攻关项目（SB201903014，LHGJ20191263）
更新日期/Last Update: 2021-11-25